MedTrace Logo

Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients

NCT02268526 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.

Conditions

  • HCMV

Interventions

BIOLOGICAL

CSJ148

CSJ148 IV q 4weeks

DRUG

Placebo

Placebo IV q 4weeks

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-02
Primary Completion
2016-12-07
Completion
2016-12-07
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Germany
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02268526 on ClinicalTrials.gov